Cadila Healthcare has received final approval to market Metoprolol Succinate extended-release tablets, from USFDA in the strengths of 25mg, 50mg, 100mg and 200mg.
The tablet will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. It is used to treat chest pain, heart failure and high blood pressure.
Moreover, the group has now more than 185 approvals and has till now filed over 320 ANDAs, since the start of the filling process in FY 2003-2004.
